Needle Free Drug Delivery Devices Market 2024 Needle Free Drug Delivery Devices Market 2024

Needle Free Drug Delivery Devices Market is expected to reach USD
14.6 billion by 2024: Radiant Insights, Inc
The global needle free drug delivery devices market is expected to reach USD 14.6 billion by 2024,
according to a new report published by Grand View Research, Inc. The increasing prevalence of chronic
diseases such as Hepatitis B, Hepatitis C, and AIDS due to the extensive use of injections is a potent
driver of the needle-free drug delivery devices market.
Additionally, the rising need for self-administration of drugs as in the case of diabetes and pain-free drug
delivery have consequentially boosted the industry share of needle-free drug delivery devices.
Moreover, controlled dosing ability, minimal damage to skin and rapid drug administration are the key
associated benefits driving the physician preference thereby fueling the demand for the market.
Furthermore, the increasing focus on the development of portable delivery devices has a high, positive
impact on the needle-free drug delivery devices market.
These aforementioned advantages related to needle-free drug delivery devices are expected to serve as
key driving factors spurring the growth of the needle-free drug delivery devices market over the forecast
period.
View Full Report with TOC @ http://www.radiantinsights.com/research/needle-free-drug-deliverydevices-market
Further key findings from the study suggest:
Jet injectors dominated the technology segment with a market share of over 30.0%, with respect to
revenue in 2015, owing to its high usage rate and wide applicability in delivering a large range of drugs
On the basis of application, the insulin delivery devices segment held the largest share of over 33.0% in
2015 owing to the high demand for painless insulin delivery by patients coupled with the requirement of
insulin at regular intervals in diabetic patients, thus facilitating the growth of this segment. As per the
WHO, the global diabetes prevalence is rising at a rate of 8.5%, thereby propelling the demand for
needle-free insulin delivery devices.
In 2015, North America dominated the needle-free drug delivery devices market at over 43.0%. The
presence of multinational conglomerates, favorable reimbursement policies, and sophisticated healthcare
infrastructure are key growth drivers of this regional market
Asia Pacific is expected to be growing at the fastest CAGR of over 12.0% during the forecast period
owing to the rising disposable income and the increasing number of investments by the western
manufactures in the emerging economies pertinent to manufacturing facilities and untapped opportunities
Some key players operational in this industry include PharmaJet, Valeritas, Antares Pharma, Inc., Bioject
Medical Technologies, Inc., 3M, Glide Pharmaceutical Technologies Ltd., Zogenix, Inc., Akra Dermojet,
Injex Pharma AG, PenJet Corporation, and D'Antonio Consultants International, Inc.